» Articles » PMID: 20657448

Lead Generation and Optimization Based on Protein-ligand Complementarity

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2010 Jul 27
PMID 20657448
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

This work proposes a computational procedure for structure-based lead generation and optimization, which relies on the complementarity of the protein-ligand interactions. This procedure takes as input the known structure of a protein-ligand complex. Retaining the positions of the ligand heavy atoms in the protein binding site it designs structurally similar compounds considering all possible combinations of atomic species (N, C, O, CH(3), NH, etc). Compounds are ranked based on a score which incorporates energetic contributions evaluated using molecular mechanics force fields. This procedure was used to design new inhibitor molecules for three serine/threonine protein kinases (p38 MAP kinase, p42 MAP kinase (ERK2), and c-Jun N-terminal kinase 3 (JNK3)). For each enzyme, the calculations produce a set of potential inhibitors whose scores are in agreement with IC50 data and Ki values. Furthermore, the native ligands for each protein target, scored within the five top-ranking compounds predicted by our method, one of the top-ranking compounds predicted to inhibit JNK3 was synthesized and his inhibitory activity confirmed against ATP hydrolysis. Our computational procedure is therefore deemed to be a useful tool for generating chemically diverse molecules active against known target proteins.

Citing Articles

Fragment-based drug discovery: opportunities for organic synthesis.

St Denis J, Hall R, Murray C, Heightman T, Rees D RSC Med Chem. 2021; 12(3):321-329.

PMID: 34041484 PMC: 8130625. DOI: 10.1039/d0md00375a.

References
1.
Wang J, Wolf R, Caldwell J, Kollman P, Case D . Development and testing of a general amber force field. J Comput Chem. 2004; 25(9):1157-74. DOI: 10.1002/jcc.20035. View

2.
Gehlhaar D, Moerder K, Zichi D, Sherman C, Ogden R, FREER S . De novo design of enzyme inhibitors by Monte Carlo ligand generation. J Med Chem. 1995; 38(3):466-72. DOI: 10.1021/jm00003a010. View

3.
Renner S, Schneider G . Scaffold-hopping potential of ligand-based similarity concepts. ChemMedChem. 2006; 1(2):181-5. DOI: 10.1002/cmdc.200500005. View

4.
Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

5.
Scapin G, Patel S, Lisnock J, Becker J, LoGrasso P . The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem Biol. 2003; 10(8):705-12. DOI: 10.1016/s1074-5521(03)00159-5. View